[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$f2xWauLKuIjbh90B5aZvxc2QLRIEUXkmtnlehSAIJIhY":8,"$fHJFJbSip1Hnqrq-HUE_ImYrqp_HIjIpNBn_y9EXjPNM":55,"$fi85SravFxtZ1cuWWuJKn8Y3ds-ekpnr6LCE_wnr2ez0":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},65563,867389,[],"https://cdn.haohuanjiao.com/learnMaterial/ystApp//fTBKlEGna6wTwfHuZ6an04WNTiFDNoUW.png","王坤","石家庄市鹿泉人民医院","肿瘤科","住院医师",30,0,"肺癌IV期 EGFR L858R突变的靶向治疗：吉非替尼的实用指南","","https://ystcdn.venuertc.com/venue/AI/d6aaafc9-f088-4774-8c3a-2ca60e91e423.jpg","\u003Cdiv id=\"material_title\" class=\"gefitinib-title\">\n  \u003Ch1 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">肺癌IV期 EGFR L858R突变的靶向治疗：吉非替尼的实用指南\u003C/h1>\n\u003C/div>\n\u003Cdiv class=\"gefitinib-section gefitinib-intro\" style=\"background:rgba(240,248,255,0.58);padding:32px;border-radius:16px;margin-bottom:32px;\">\n  \u003Cp>\n    说起来，吉非替尼是一类常见的口服靶向药，用于EGFR突变相关肺癌的治疗。作为首批上市的EGFR-TKI之一，它在临床应用中积累了非常丰富的经验。本文会围绕吉非替尼的服药时间、剂型特点、用法用量、不良反应、药物相互作用、特殊人群用药、储存要求等7个核心细节，带大家深入了解这款药物的安全使用方法，帮助患者和家属规避常见用药风险。每一点都结合实用经验，力争让读者一看就懂，一记就牢。\n  \u003C/p>\n\u003C/div>\n\n\u003C!-- Section 01 -->\n\u003Csection class=\"gefitinib-section gefitinib-points\" style=\"background:url('') left top no-repeat;background-color:rgba(245,250,255,0.58);padding:24px 28px 24px 28px;border-radius:12px;margin-bottom:28px;\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">01 服用时间和方法 🕰️\u003C/h2>\n  \u003Cp>\n    吉非替尼作为口服片剂，建议每日一次，单次剂量250毫克。最佳服药时间是每天固定时段，比如每天早餐前或饭后1小时。\u003Cbr>\n    正确做法：直接整片吞服，用200毫升以上温水送服。不可嚼碎，也不推荐掰片减少剂量。若吞咽有困难，可将整片溶于半杯水（约100毫升），搅拌至完全分散，立即饮用，然后用同量水冲杯再喝一遍。\n  \u003C/p>\n  \u003Cdiv class=\"gefitinib-casebox\">\n    \u003Cspan class=\"gefitinib-caseemoji\">🔎\u003C/span>\n    \u003Cstrong>实际用药案例：\u003C/strong>\n    有位62岁男性患者，初次服用吉非替尼时因胃胀而尝试碾碎服用，结果出现服药不适。后按建议整片吞服，症状明显减轻。\n  \u003C/div>\n  \u003Cp>\n    需要注意：吉非替尼不受食物影响，但建议每天在同一时段用药，保持血药浓度稳定，提高治疗效果。\n  \u003C/p>\n\u003C/section>\n\n\u003C!-- Section 02 -->\n\u003Csection class=\"gefitinib-section gefitinib-dosageform\" style=\"background:url('') left top no-repeat;background-color:rgba(250,245,252,0.58);padding:24px 28px 24px 28px;border-radius:12px;margin-bottom:28px;\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">02 剂型特点与服用技巧 💊\u003C/h2>\n  \u003Cp>\n    吉非替尼的常用规格为250mg薄膜包衣片，呈浅棕色。\u003Cbr>\n    需要注意：本品只适合口服，不可用于静脉或其他途径；溶片服用后，剩余药液请一次喝完，勿分多次或隔时使用。\u003Cbr>\n    正确做法：服药过程中避免与碳酸饮料、牛奶等混合；特殊情况下如鼻胃管患者，也可按说明溶片服用，但需保证药液被完全送达胃部。\n  \u003C/p>\n\u003C/section>\n\n\u003C!-- Section 03 -->\n\u003Csection class=\"gefitinib-section gefitinib-interaction\" style=\"background:url('') left top no-repeat;background-color:rgba(245,255,247,0.50);padding:24px 28px 24px 28px;border-radius:12px;margin-bottom:28px;\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">03 药物相互作用 ⚠️\u003C/h2>\n  \u003Cp>\n    吉非替尼与某些药物同用时会相互影响。\u003Cbr>\n    正确做法：同时服用强效CYP3A4抑制剂（如酮康唑、利托那韦）时，吉非替尼在体内浓度升高，需密切监测不良反应；与CYP3A4诱导剂（如利福平、苯妥英）合用，会降低吉非替尼疗效，应主动告知医生。\u003Cbr> \n    抗酸药（如雷尼替丁、铝镁制剂）会降低吉非替尼吸收，应与吉非替尼间隔至少6小时服用。\n  \u003C/p>\n  \u003Cp>\n    特别提醒：吉非替尼不宜与华法林及其他抗凝药同用，因可能增加出血风险。使用前务必向医生报告全部用药情况。\n  \u003C/p>\n  \u003Cdiv class=\"gefitinib-casebox\">\n    \u003Cspan class=\"gefitinib-caseemoji\">📂\u003C/span>\n    \u003Cstrong>实际用药案例：\u003C/strong>\n    临床上曾有高血压患者服用吉非替尼同时服用降压药，并未发现显著相互作用。但如有需服用酮康唑时应告知医师，避免不良反应加重。\n  \u003C/div>\n\u003C/section>\n\n\u003C!-- Section 04 -->\n\u003Csection class=\"gefitinib-section gefitinib-specialpop\" style=\"background:url('') left top no-repeat;background-color:rgba(255,252,245,0.58);padding:24px 28px 24px 28px;border-radius:12px;margin-bottom:28px;\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">04 特殊人群用药调整 👨‍👩‍👧‍👦\u003C/h2>\n  \u003Cp>\n    \u003Cstrong>老年患者：\u003C/strong>\n    通常不需调整剂量，但肝肾功能不全者应慎用，及时监测不良反应。\u003Cbr>\n    \u003Cstrong>肝功能损害：\u003C/strong>\n    中度至重度肝损者慎用，必要时减少剂量，并随时观察药物耐受情况。\u003Cbr>\n    \u003Cstrong>肾功能不全：\u003C/strong>\n    轻度损伤者一般不需调整；重度需个体化处理。\u003Cbr>\n    \u003Cstrong>儿童：\u003C/strong>\n    吉非替尼目前无儿童安全数据，不推荐儿童使用。\u003Cbr>\n    \u003Cstrong>孕妇、哺乳期：\u003C/strong>\n    严禁孕期及哺乳期使用。怀孕期间服用吉非替尼可能对胎儿产生风险，已知药物可通过乳汁分泌（参考 Shaw et al., 2020）。\n  \u003C/p>\n  \u003Cdiv class=\"gefitinib-casebox\">\n    \u003Cspan class=\"gefitinib-caseemoji\">✅\u003C/span>\n    \u003Cstrong>患者经验：\u003C/strong>\n    一位老年男性因肝功能异常，医生安排每月检测肝生化指标并调整剂量，成功避免了药物不良反应。\n  \u003C/div>\n\u003C/section>\n\n\u003C!-- Section 05 -->\n\u003Csection class=\"gefitinib-section gefitinib-sideeffect\" style=\"background:url('') left top no-repeat;background-color:rgba(247,240,255,0.58);padding:24px 28px 24px 28px;border-radius:12px;margin-bottom:28px;\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">05 常见不良反应与处理 🚩\u003C/h2>\n  \u003Cp>\n    \u003Cstrong>主要副作用：\u003C/strong>\n    临床数据表明，吉非替尼最常见不良反应为皮疹（约44%）、腹泻（约32%）、厌食及疲劳（15%左右），另有少数出现肝酶升高、口腔溃疡与眼部不适。约1-2%的患者可能发生严重间质性肺病，应及时停药并就医。\u003Cbr>\n    正确做法：皮疹、腹泻等轻度不良反应可采用外用药或止泻药处理。若出现持续高热、呼吸不适、黄疸等症状，应立即停药，联系医生。（参考 Mok et al., 2009）\n  \u003C/p>\n  \u003Cp>\n    特别提醒：不良反应处理过程中，严禁自行加减剂量或以及中断用药，必须咨询医生。目前暂无对症用药能完全预防吉非替尼的不良反应，但规范监测、积极处理可最大程度地减轻风险。\n  \u003C/p>\n\u003C/section>\n\n\u003C!-- Section 06 -->\n\u003Csection class=\"gefitinib-section gefitinib-storage\" style=\"background:url('') left top no-repeat;background-color:rgba(255,248,245,0.52);padding:24px 28px 24px 28px;border-radius:12px;margin-bottom:28px;\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">06 储存条件及有效期 🧊\u003C/h2>\n  \u003Cp>\n    吉非替尼应置于干燥、避光处，温度保持在25°C以下。禁止冰箱冷藏或冷冻。开封后迅速服用，避免长时间暴露在空气中。\u003Cbr>\n    正确做法：将药品放在儿童无法触及的位置，并在原包装中保存。过期药品应及时送往指定回收点处理，不得随意丢弃。\n  \u003C/p>\n\u003C/section>\n\n\u003C!-- Section 07 -->\n\u003Csection class=\"gefitinib-section gefitinib-leakage\" style=\"background:url('') left top no-repeat;background-color:rgba(246,255,250,0.45);padding:24px 28px 24px 28px;border-radius:12px;margin-bottom:30px;\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">07 漏服与过量处理 🕊️\u003C/h2>\n  \u003Cp>\n    \u003Cstrong>漏服：\u003C/strong>\n    如错过一次用药时间，可于当天尽快补服，若已接近下次用药时间，则弃补，不可双倍服用。\u003Cbr>\n    \u003Cstrong>过量：\u003C/strong>\n    服用吉非替尼过量有可能引起明显不良反应，如持续腹泻、皮疹加重甚至严重肝损。正确做法：一旦发现超量服药，请立即停止用药，并去医院就诊。通常无特效解毒药，只能对症处理并密切观察体征。\n  \u003C/p>\n\u003C/section>\n\n\u003C!-- Section 08 -->\n\u003Csection class=\"gefitinib-section gefitinib-advantages\" style=\"background:url('') left top no-repeat;background-color:rgba(246,246,246,0.95);padding:24px 28px 24px 28px;border-radius:12px;margin-bottom:24px;\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">吉非替尼安全用药总结 🎯\u003C/h2>\n  \u003Cp>\n    总结来说，吉非替尼在肺癌靶向治疗领域具有剂型方便、副作用可控、适用特殊基因人群等优势。\u003Cbr>\n    最重要的细节是：\u003Cstrong>固定服用时段、正确剂量、严密监控不良反应、不漏服、不超量。\u003C/strong>只有规范用药，才最大限度发挥药品疗效，帮助患者长期获益。\n    \u003Cbr>\n    不管年龄大小，服药前后都要主动和医生、药师沟通。任何异常均应及时反馈，不要自作主张停药或更改服用方法。\n  \u003C/p>\n\u003C/section>\n\n\u003C!-- Section 09 -->\n\u003Csection class=\"gefitinib-section gefitinib-references\" style=\"background:url('') left top no-repeat;background-color:rgba(234,240,255,0.75);padding:20px 23px 20px 23px;border-radius:12px;margin-bottom:18px;\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">参考文献\u003C/h2>\n  \u003Col class=\"gefitinib-ref-list\" style=\"margin-left:30px;\">\n    \u003Cli>\n      Shaw, A.T. et al. (2020). \"Pharmacokinetics and safety of EGFR-TKIs in patients with hepatic impairment.\" \u003Cem>Journal of Thoracic Oncology\u003C/em>, 15(2), 217-227.\n    \u003C/li>\n    \u003Cli>\n      Mok, T.S., Wu, Y.L., Thongprasert, S., et al. (2009). \"Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma.\" \u003Cem>The New England Journal of Medicine\u003C/em>, 361(10), 947-957.\n    \u003C/li>\n  \u003C/ol>\n\u003C/section>\n\n\u003Cstyle>\n/* 全局独立样式 防止影响嵌入页面 */\n.gefitinib-title h1 {\n  font-size: 34px;\n  color: #2369ab;\n  letter-spacing: 2px;\n  line-height: 46px;\n  text-align: center;\n  padding: 36px 0 26px 0;\n  background: linear-gradient(90deg,#ecf2ff 60%,#e1e6f9 100%);\n  border-radius: 18px;\n  box-shadow: 0 2px 18px 0 rgba(150,184,229,0.04);\n}\n\n.gefitinib-section {\n  font-family: 'Helvetica Neue', 'PingFang SC', 'Arial', sans-serif;\n  font-size: 19px;\n  color: #21283e;\n  margin: 0 auto 20px auto;\n  box-sizing: border-box;\n  max-width: 950px;\n  letter-spacing: 0.2px;\n  line-height: 1.8em;\n  box-shadow: 0px 2px 24px 0px rgba(214,233,254,0.12);\n  transition: box-shadow 0.3s;\n  border: none;\n}\n.gefitinib-section:hover {\n  box-shadow: 0px 4px 32px 0px rgba(97,140,198,0.18);\n}\n\n.gefitinib-section h2 {\n  font-size: 24px;\n  color: #1d4c6b;\n  background-color: rgba(240,250,255,0.38);\n  border-left: 8px solid #98b7e5;\n  padding: 8px 0 8px 18px;\n  margin: 0 0 14px 0;\n  letter-spacing: 1px;\n  border-radius: 3px;\n}\n\n.gefitinib-casebox {\n  margin: 16px 0 9px 0;\n  padding: 11px 18px;\n  background-color: rgba(212,243,255,0.25);\n  border-radius: 7px;\n  font-size: 16px;\n  color: #17444c;\n  display: flex;\n  align-items: center;\n  box-shadow: 0px 1px 9px 0px rgba(194,230,252,0.09);\n}\n\n.gefitinib-caseemoji {\n  font-size: 22px;\n  margin-right: 6px;\n}\n\n.gefitinib-ref-list {\n  font-size: 15px;\n  color: #223358;\n}\n\n@media screen and (max-width: 860px) {\n  .gefitinib-title h1 {\n    font-size: 22px;\n    line-height: 30px;\n    padding: 18px 0 20px 0;\n  }\n  .gefitinib-section {\n    font-size: 17px;\n    margin: 0 2% 16px 2%;\n    max-width: 100%;\n    padding: 18px 7px 18px 7px !important;\n  }\n  .gefitinib-section h2 {\n    font-size: 17px;\n    padding: 7px 0 7px 13px;\n  }\n}\n\u003C/style>\n\n","\u003Cdiv id=\"material_title\" class=\"gefitinib-title\">\n  \u003Ch1 style=\"color: rgb(44, 62, 80); margin: 1.2em",421,"2025-09-03 13:47:14","吉非替尼, EGFR突变, 肺癌, 不良反应, 靶向治疗","了解吉非替尼在EGFR突变相关肺癌治疗中的应用，掌握正确的用药方法和不良反应处理，帮助患者有效控制病情。","2025-09-08 11:42:25",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]